A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474.
An introductory clinical trial of the anti-oestrogenic agent IC146474 in late or recurrent carcinoma of the breast is described.Forty-six patients have been treated, of whom 10 have shown a good response. This is of the same order as that seen with oestrogens and androgens.The particular advantage of this drug is the low incidence of troublesome side effects.
D000328:Adult; D000368:Aged; D000475:Alkenes / Q000627:therapeutic use; D045930:Anabolic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D002908:Chronic Disease; D004054:Diethylstilbestrol / Q000009:adverse effects / Q000627:therapeutic use; D004965:Estrogen Antagonists; D005021:Ethylamines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D012008:Recurrence
D000475:Alkenes; D045930:Anabolic Agents; D004965:Estrogen Antagonists; D005021:Ethylamines; D004054:Diethylstilbestrol